LIXTE Biotechnology Holdings (NASDAQ: LIXT) is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event scheduled for Feb. 19 at Morehouse College in Atlanta. The summit, inspired by the music and legacy of De La Soul, brings together leaders in health, culture, science, and community to advance health equity for Black men and families. It is rooted in De La Soul’s song “Good Health,” written after the passing of founding member David Jolicoeur (Trugoy the Dove).
Developed in collaboration with Blacksmith holdings, the program reflects De La Soul’s evolution from musical pioneers to wellness advocates. Discussions will span cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness. LIXTE said the summit aligns with its mission as a clinical-stage pharmaceutical company advancing cancer care through its first-in-class oncology compound LB-100 and its European research subsidiary, LIORA, while creating a space to connect scientific innovation with communities most impacted by health disparities. To view the full press release, visit https://ibn.fm/0kkqK.
This sponsorship highlights LIXTE’s commitment to addressing health disparities that disproportionately affect Black communities. According to the American Cancer Society, Black men have the highest cancer death rates among all racial and ethnic groups in the United States. By partnering with cultural icons like De La Soul and an academic institution like Morehouse College, LIXTE aims to bridge the gap between cutting-edge cancer research and the communities that need it most.
LIXTE’s lead compound, LB-100, is a first-in-class PP2A inhibitor that has shown promise in preclinical studies for enhancing chemotherapies and immunotherapies. The company is currently conducting proof-of-concept clinical trials for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company’s approach, termed “activation lethality,” represents a new paradigm in cancer biology, covered by a comprehensive patent portfolio. More information about LB-100 can be found at www.lixte.com.
The summit’s focus on health equity is timely, as recent data from the Centers for Disease Control and Prevention show that Black men are 15% more likely to die from cancer than white men. LIXTE’s involvement underscores the importance of engaging communities in clinical research and health education. The event will also address other critical health issues such as heart disease, mental health, and addiction, which disproportionately affect Black families.
LIXTE’s sponsorship of the Good Health Summit is a strategic move to raise awareness about its clinical programs while addressing the social determinants of health. As a clinical-stage company, LIXTE faces risks and uncertainties inherent in drug development, as outlined in its filings with the Securities and Exchange Commission. However, this initiative demonstrates its broader commitment to health equity beyond the laboratory.
